Neuberger Berman Group
LUMO

Neuberger Berman Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Neuberger Berman Group’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,333
Closed -$305K – 1827
2017
Q3 		$305K Buy
+3,333
New +$256K ﹤0.01% 1411

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Neuberger Berman Group's LUMO Position: Q4 2017 in Review

Neuberger Berman Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2017, closing a stake of 3,333 shares — an estimated $305K sold.

Neuberger Berman Group first reported a position in LUMO in Q3 2017 and held it in 1 quarter. The position peaked at $305K in Q3 2017. 130 funds tracked by Wall St. Rank hold LUMO as of Q4 2017.

  • Neuberger Berman Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Neuberger Berman Group sold 3,333 Lumos Pharma, Inc. Common Stock shares in Q4 2017, an estimated $305K.
  • Neuberger Berman Group first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Neuberger Berman Group's Lumos Pharma, Inc. Common Stock position peaked at $305K in Q3 2017.
  • 130 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2017.

Based on Neuberger Berman Group's 13F filing for Q4 2017, filed 14 Feb 2018.